Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/26
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive PatientsGlobeNewsWire • 05/14/26
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference CallGlobeNewsWire • 05/07/26
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant CohortGlobeNewsWire • 05/01/26
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/25/26
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference CallGlobeNewsWire • 03/18/26
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer DrugThe Motley Fool • 03/13/26
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical OncologyGlobeNewsWire • 03/09/26
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/09/26
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC FilingThe Motley Fool • 03/06/26
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two PositionThe Motley Fool • 02/22/26
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptSeeking Alpha • 02/13/26
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price JumpThe Motley Fool • 02/06/26
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast CancerGlobeNewsWire • 01/20/26